TRVI · Trevi Therapeutics, Inc.

Current Thesis

Trevi Therapeutics’ Haduvio recovery case requires OCEAN-2 to start within the guided third quarter and the shares to regain $16 on a weekly close before a weekly close below $13 ends that case. This is a narrower recovery hypothesis: the previous breakout thesis failed when the market closed at $14.95 on 2026-09-18, below its published $16 weekly invalidation threshold.

As an interpretation of that breach, the narrative is dead in its prior breakout form — the 2026-09-18 close invalidated the structure described in the 2026-09-06 dossier. That market failure does not establish a clinical failure. At the 2026-09-15 Morgan Stanley conference, CEO Jennifer Good still described the second OCEAN trial as starting during the quarter; initiation remained a management commitment in that discussion. September 15 management transcript

Bullish and bearish views on Trevi Therapeutics, Inc.

The model's bull view on Trevi Therapeutics, Inc. (TRVI), in brief: Funding supports the development schedule. The bear view: The published structure already failed. The supplied adjusted price series shows a $14.95 close on 2026-09-18, a three-month decline of 15.6% and a close 23.3% below the reported $19.50 annual high. Those observations supersede the earlier breakout description. Pivotal results… Both cases follow in full.

Bull Case

• Funding supports the development schedule. Trevi reported $318.9 million in cash and marketable securities at 2026-06-30 and guided funding into 2030 in its 2026-08-06 results. That is management’s runway forecast, not evidence of eventual approval. Second-quarter results
• The next commitment remains identifiable. Good reiterated the quarterly initiation timetable on 2026-09-15. Chief Development Officer James Cassella described OCEAN-2 as a 200-patient trial with a 12-week primary efficacy endpoint, making initiation an operational milestone rather than an efficacy result. September 15 management transcript

Bear Case

• The published structure already failed. The supplied adjusted price series shows a $14.95 close on 2026-09-18, a three-month decline of 15.6% and a close 23.3% below the reported $19.50 annual high. Those observations supersede the earlier breakout description.
• Pivotal results remain distant. Trevi’s 2026-08-06 release guided OCEAN-2 topline results to the second half of 2027 and OCEAN-1 results to the first half of 2028. Initiation alone cannot establish the efficacy or durability those trials must test. Second-quarter results
• Ownership filings require careful interpretation. Trevi’s filing index lists a Form 144 on 2026-09-15 and a Form 4 on 2026-09-17. The index establishes filing activity; it does not establish the transaction terms or justify attributing the price decline to insider transactions. Company filing index

Setup & Price Structure

The measured reference is the supplied 2026-09-18 adjusted close of $14.95. The 14-day relative strength index (RSI) was 24.6 on that date. That momentum reading does not establish a reversal; no current moving-average value was supplied, so distance above or below a rising average cannot be stated.

The $16 threshold is the failed June breakout shelf identified in the 2026-09-06 dossier. A weekly close above $16 would be the specified price confirmation for the separate recovery case. Its lower boundary is $13, the lower edge of the historical post-offering range documented in that dossier; current support at that level has not been demonstrated. This boundary does not replace or erase the already-triggered $16 invalidation.

The company calendar records investor appearances on 2026-09-10, 2026-09-14 and 2026-09-15; the supplied September 18 close followed that concentration of exposure. This establishes conference clustering, not crowded ownership or a causal explanation for the decline. No current short-interest or retail-participation measurement is available in the evidence. Company event calendar

Catalyst Calendar (next 30 days)

• 2026-09-30 — Quarterly execution checkpoint. This is the end of the OCEAN-2 initiation window reiterated by management on 2026-09-15, not an announced event date. A disclosed start after this date would miss that timetable; silence alone would leave initiation unverified. September 15 management transcript
• 2026-10-01 — IPF Summit panels. Trevi’s 2026-09-03 announcement scheduled Cassella’s participation in Boston. The appearance provides a dated opportunity for an operational update; the announcement does not designate it as a pivotal efficacy release. September conference announcement

What Would Change Our Mind

Loss of the historical post-offering range would end the separate recovery hypothesis: a weekly close below $13 is its price invalidation. The original thesis remains invalidated by the 2026-09-18 close below $16, regardless of subsequent trial announcements.

The recovery case would be fulfilled only by confirmation that OCEAN-2 started by 2026-09-30 and a subsequent weekly close above $16 before the lower boundary is breached. A company disclosure moving initiation beyond the third quarter would independently invalidate the execution premise. No announcement by quarter-end would leave that premise unconfirmed, rather than prove that the trial had not started.

Correlation Notes

This is a single-company clinical-development case, consistent with the absence of an active peer-theme grouping in the 2026-09-20 coverage context. No paired sector-return series accompanies the 2026-09-18 price observations, so a numerical beta or a claim that biotechnology-sector weakness caused the decline is unsupported. The conference dates and the subsequent close are too small a sample to support a causal claim about investor marketing and returns.